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Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a
most frequent type of leukemia of adults in Western
world [1]. Since it is a slow growing malignancy, the
time allows for an immunotherapy attempts against the
tumor cells to be generated by vaccination [2,3]. It is
easy to obtain tumor cells for vaccine production, as
the leukemia cells circulate in large amounts in periph-
eral blood. The positive clinical observations in
patients vaccinated with the irradiated autologous
leukemia cells could be explained by hypothesis of
dendritic cells (DC) activity [4,5]. DCs are the most
potent cancer antigen's presenting cells that initiate
effective T-cell response [6,7] observed as the result of
these vaccinations. The active DCs have been shown
in clinical observations of melanoma and prostate car-
cinoma [8,9,10]. They have also been used with some
success to generate an immune response against idio-
type peptides in patients with follicular B-cell lym-
phoma [11]. It has been shown that functional DCs can
be generated from peripheral blood monocytes of B-
CLL patients in early stages of the disease [12,13]. The
DCs stimulated with tumor antigens from leukemic
cell lysates or apoptotic bodies induced in vitro strong
response of specific cytotoxic T lymphocytes (CTLs)
[14,15].
Several problems of DCs activity are unknown, and
may be asked in model experiments. SCID (severe
combined immunodeficiency) mice have been proved
a useful model for studies of autoimmune diseases as
well as cancer diseases, including B-CLL [16,17]. We
established a SCID mouse xenotransplant model to
study the effect of DCs on human BCLL cells counts
[18]. In the present study, we implanted leukemic cells
into peritoneal cavity of SCID mice, then the animals
received human autologous or allogeneic monocyte-
derived DCs pulsed with tumor cell lysates or irradiat-
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ed leukemia cells in order to compare in vivo thera-
peutic potential of both DCs vaccines in B-CLL.
Materials and methods
Mice. The pathogen-free, 10-12 weeks-old severe combined
immunodeficient (SCID) mice (BALB/c C.B-17/IcrHanHsd-scid
[19] were our own breeding; first families were from Harlan
Shaw's Farm, UK. The animals were housed in sterilized
microisolator cages and received vitamins, autoclaved food and
drinking water. The mice were systematically controlled for the
absence of peripheral blood B and T lymphocytes with anti-
mouse CD19 PE (clone ID3) and anti-mouse CD3 FITC (clone
17A2), (Pharmingen).
Before the implantation of human cells the animals were
immunosupressed by s.c. injection of cyclofosfamide, 3mg/animal
on the day 3 and the day 2 before inoculation of the human cells
[20,21]. Then the animals were treated every 2-3 days s.c. with
hybridoma PK136 cells culture supernatant containing the anti-
NK1.1 monoclonal antibodies (4 μg IgG) to suppress mice NK
cells activity [22]. The experiment protocol was accepted by Local
Ethic Commision for Animal Experiments (Nr KE 271/2003).
Cell donors: leukemic patients and healthy donors. B-cells for
implantation were obtained from untreated patients in 0-2 stage
according to Rai [23] (Table 1). The peripheral blood samples (20
ml) were collected on heparin after informed consent obtained
from the patient in accordance with the Declaration of Helsinki and
with the approval by the Local Ethics Committee of the Medical
University at Lublin (KE-0254/239/2002). The peripheral blood
samples (40ml) from patients and healthy donors for preparation of
dendritic cells were collected similarly. 
Preparation of cells for implantation. Leukemia B-CLL cells
were present in mononuclear fraction obtained by the Lymphoprep
(Nycomede, Oslo, Norway) density gradient centrifugation for 20
min at 200xg. The number of mononuclear living cells was count-
ed in propidium iodide cytometric test [24]. Monoclonal antibod-
ies to antigens present on human lymphocytes, all from Becton
Dickinson, were used to evaluate the number of HLAABC positive
cells (clone G46-2.6), CD45+ cells (clone 2D1, IgG1), B-cells
CD19+ (clone 4G7, IgG1), leukemia B-cells CD5+/CD19+ (clones
L17F12/SJ25C1, IgG2a/IgG1), and normal CD3+ T lymphocytes
(clone SK7, IgG1) with the cytometer. The isotype control anto-
bodies were applied as well.
Implantation of B-CLL and dendritic cells. The patient periph-
eral blood mononuclear cells, 12-25 × 106/animal containing
known number of leukemia B-cells and T cells were implanted
intraperitoneally (ip) at day zero. The 13 out of 27 B-CLL
xenografted mice served as controls and investigated 14 days later
while the 14 of them were implanted on the day 7 with human cell
suspension containing the DCs prepared as described below and
investigated 7 days later.
Generation of autologous and allogeneic DCs. Dendritic cells were
generated from peripheral blood monocytes according to previous-
ly described procedures [13]. Briefly, mononuclear cells isolated
from 40 mL of peripheral blood taken from patients with BCLL
and healthy donors were used. Cells were allowed to adhere to
plastic dishes for 90 min. at 37°C. Thereafter the adherent fraction
of PBMC was cultured in a medium containing RPMI-1640 sup-
plemented with 2% human albumin (ZLB Bioplasma AG, Bern,
Switzerland), penicillin 100 IU /ml, streptomycin 50mg/ml,
neomycin 100mg/ml). On day 1, 3 and 5 of the culture, 1.000
IU/ml rhGM-CSF (Leucomax, Novartis, Basel, Switzerland) and
500 ng/ml rhIL-4 (Strathmann, Hannover, Germany) were added to
the culture medium. On day 6, the lysates of 7x107 autologous
leukemic B-cells were used for the pulsing of the DCs. On day
seven, 50 ng/ml rhTNF-α was added to the culture and the cells
were stimulated for 2 h. Thereafter cells were collected, washed
twice in 0.9% NaCl and resuspended in 0.5-1.0 mL of 0.9% NaCl.
Before implantation, the suspension of DCs cell populations were
analyzed as described for PBMC, and finaly DCs at a dose: DCau-
to 0.5 to 14 × 106 , while DCallo 0.2 to 2 × 106 cells per mouse
were injected intraperitoneally. Characterization of the dendritic
cells suspensions are in Table 2 (see results).
Analysis of B-CLL counts after autologous and allogeneic DCs
implantation. At day 14 from implantation of PBMC, and 7 from
implantation of DCs, the number of leukemia cells in peritoneal cav-
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Table 1. Clinical and laboratory characteristics of B-CLL patients, whose cells were implanted into SCID mice. Normal range of
WBC/lymphocytes: 4-10/0.8-4.3(G/l).   2-M  0.8-2.2mg/L; abnormal values are marked with asterisk for ZAP-70, CD38,  2-M; stages
according to Rai [23]; clinical response for autoDC vaccines (see results): RS – response, SD – stable disease, NR – no response; Abbre-
viations: N – normal; ND – not done, NT – not treated.
Normal range of WBC/lymphocytes: 4-10/0.8-4.3(G/l). β2-M  0.8-2.2mg/L; abnormal values are marked with asterisk for ZAP-70, CD38, β2-M; stages
according to Rai [23]; clinical response for autoDC vaccines (see results): RS – response, SD – stable disease, NR – no response; Abbreviations: N – nor-
mal; ND – not done, NT – not treated;
ity of the animal was analyzed. First the animal was sacrified, then
the peritoneal cavity was washed out with 2 ml of the sterile physi-
ological salt solution and cells were analyzed in that suspension.
Flow cytometry and statistics. The number of peritoneal cavity
cells was counted and the number of human populations CD45+,
CD5+/CD19+, and CD3+ per animal were analyzed as described
above for cells before implantation. Cross-reaction of the antihu-
man leukocyte antibodies with mice leukocytes was not observed.
The cells were analyzed by flow cytometry (Becton Dickinson
FACSCalibur) in CellQuest application (3.2.1f1). Nonparametric
statistics was used. The median value and percentile values (P25
and P75) were calculated for results of experiments and the statis-
tically significant difference of results was assumed for p<0.05 in
Mann-Whitney U-test.
Results
The characteristics of chronic B-lymphocytic
leukemia patients participating in experiments with
DC are summarized in Table 1. All patients, 47-69
years old, were diagnosed with B-CLL in early stages
(Rai 0-2), according to NCI (National Cancer Institute)
criteria, and were previously untreated. The results of
peripheral blood leukocytes and laboratory tests of
patients including analyzes of leukemia cells ZAP-70
and CD38 were assayed.
The patients were treated later clinically with auto-
logical DCs vaccines and the clinical result of treat-
ment is included in the Table 1. The patients who
showed a 25% or higher reduction in their WBC count
after vaccination were considered responders (RS),
patients with less than 25% reduction – stable disease
(SD), and patients with an increase of their WBC – non
responders (NR). Most patients responded for the DCs
vaccines with stable disease (SD).
Evaluation of conditions for the experiment
In the initial part of the study [18], mouse xeno-
transplant model was established. For this, SCID
mice were inoculated with B-CLL patients' PBMC at
different doses ranging from 10.0 to 150.0 × 106
cells per mouse. The optimal range of implanted
PBMC was established for 10-30 × 106/animal, as
used in the present experiments. It was observed,
that ip implanted hemopoietic cells remain locally
and are not distributed significantly to the spleen,
bone marrow or peripheral blood of the mouse [18]
(Fig.1D). Consequently, here we analyzed only cells
present in the peritoneal cavity of the animals. The
experiments were not prolonged to 21 days from
PBMC implantation because it was observed, that
the number of cells is significantly decreased
between 14 to 21 days.
With ip implants mice received patients mononu-
clear cells at the Median dose 15.5 × 106 containing
about 96% of living, CD45+ hematopoietic cells. With
implantation of dendritic cells, mice received addition-
al portion of human hemopoietic cells which rised the
number of CD45+ cells on 10% with autologous DC,
or 0.4% with allogeneic DC.
Characterization of the lymphocytes implanted
with the suspension of dendritic cells is presented in
Table 2. With allogeneic DCs the allogeneic T lym-
phocytes were applied.
The animals with implanted B-CLL cells appeared
healthy within the period of experiment. The number
of B-CLL cells and T lymphocytes implanted was a
sum of the cells given at day zero and the cells added
at day 7 with suspension of DC. The final analysis was
at day 14 from implantation of human leukemia cells
and it appeared, that from implanted cells, only 0.23 ×
106 were recoverd (1.7%) at analysis (Table 3). In two
experiments, the immunosupression with monoclonal
anti-NK1.1 only was attempted, but the suppression
was uncomplete and these results were not included in
the final analysis.
Cell populations in control animals
The number of human cell populations from different
patients in control animals is presented in Table 4.
The recovered number of human subpopulations of
hemopoietic CD45+ cells is the sum of leukemia B
cells CD19+/CD5+ (333 × 103), normal T CD3+ cells
(17 × 103), and probably normal B cells (Fig.1A,B,
C). The presence of T cells subpopulation is impor-
tant for possible interaction with DCs in process of
crosspresentation and stimulation of T cells response.
In some experiments human HLAABC positive cells
were tested and were observed (not presented in
details).
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Table 2. Characterization of lymphocytes implanted ip to the mice with DCauto and DCallo. M = median values (P25-P75) = 25 and 75
percentile values.
*some CD5+/CD19+ auto "apoptotic bodies" may be present
Autologous or allogeneic DCs interaction with
lymphocytes
Results in control animals with implanted patient's
leukemia B-CLL cells without DC were compared
with that from animals with B-CLL cells from the
same patient that additionally have implanted auto-DC
or allo-DC activated with the same patient's leukemia
cells lysate  and TNF. At the day 7 from implantation
of allogeneic DC to animals, the CD45+ hemopoietic
cells and leukemia B cells CD5+/CD19+ populations
were significantly lower as compared with the control
animals (Table 5). The number of cells in the popula-
tions CD19+ B cells and CD3+ T cells had a tendency
to decrease. The result may be interpreted as in vivo
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Table 3. Number of implanted patients peripheral blood MNC and recovered human hematopoietic cells CD45+ . M = median values
(P25-P75)  = 25 and 75 percentile values.
*mean from 2-6 animals from the same patient; patient #6 was the donor for two experiments; patient #2 was excluded from calculations as the result was
analyzed at day 9th
Fig. 1. Cytometric assay of human lym-
phocytes washed out from the peri-
toneal cavity (1A, 1C, 1D) or from the
peripheral blood (1B) of the animal
analyzed 14 days after implantation of
B-CLL cells of the patient. Lympho-
cytes B CD19+ and lymphocytes T
CD3+ (1C) as well as leukemia cells
CD19+CD5+ (1B, 1D) may be recog-
nized. Note, the high number of
leukemia cells in the peritoneum (1D)
and traces of leukemia cells in the
peripheral blood (1B) of the same ani-
mal. FSC/SSC gate for mouse and
human lymphocytes is at Fig.1A. 
MLC (mixed lymphocyte culture) interaction between
patient's lymphocytes and T cells of donor DCs, some-
thing like acute graft versus host (GVH) response. It is
not the result of activating interaction between allo-
geneic DCs and patients T lymphocytes, because the
number of T cells is decreasing similarly as the num-
ber of leukemia cells.
There were no significant differences in the counts
of cell populations CD45+, CD19+, CD5+/CD19+ in
animals treated with autologous DC cells as compared
to the control animals. However, there is a tendency of
CD3+ T cells number to increase, nearly three times,
from 17×103/animal in controls to 48×103/animal in
DCs implanted, a possible result of DC autologous and
T cells activating interaction, and proliferation of T
cells. Results are presented in Table 5.
Discussion
Despite the results of in vitro studies showing that
functional DCs can be generated from peripheral blood
monocytes of patients with B-CLL [14], and the spe-
cific CTL against B-CLL cells could be achieved using
DCs pulsed with leukemic antigens [25], so far, there
was only one reported clinical trial on DCs
immunotherapy in B-CLL [13]. Therefore, we have
established a SCID mouse model to study in vivo, the
effect of DCs vaccinations on the number of B-CLL
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Table 4. The analysis of human cells populations in peritoneal cavity of particular 27 SCID mice at day 14 after ip inoculation with periph-
eral blood mononuclear cells of B-CLL patients without (control) or with post-injection (on day 7) with human allogeneic or autologous
dendritic cells (DCallo, DCauto, respectively). M = median value, (P25-P75) = 25 and 75 percentile values.
cells. In the initial part of experiment [18] we trans-
planted different doses of PBMC isolated from
patients with B-CLL with an intend to evaluate the dis-
tribution as well as the count of leukemic cells in dif-
ferent tissues, such as peripheral blood, bone marrow,
peritoneal cavity, spleen and liver. We found, that high
number of inoculated cells (150.0 × 106) induced death
of animals [18], and if the number of implanted PBMC
did not exceed 50.0-90.0 × 106/per mouse, leukemic
cells were eliminated within 60 days. Similar observa-
tions, concerning correlations between survival time
and a number of implanted B-CLL cell line were
reported by Kawata et al. [26]. We have also found
individual differences in the survival time between
animals transplanted with similar dose of cells from
different patients, resulting probably from different
activity and proliferative potential of leukemic cells in
individual patients, as well as from heterogeneic clini-
cal course of B-CLL. In the other study survival time
of SCID mice inoculated with T-CLL cells at a dose
40.0 × 106 ranged from 43 to 69 days [27]. In our
study, even higher dose was eliminated from mice that
may result from more aggressive character of T-CLL
comparing to B-CLL.
After intraperitoneal implantation of PBMC isolat-
ed from patients with B-CLL, CD19+CD5+ cells were
found at 14 days in small number in peripheral blood,
bone marrow, and spleen of mice as compared to peri-
toneal cavity [18]. In the study of Hummel et al. [17],
after intravenous injection of PBMC obtained from B-
CLL patients, leukemic cells were found the most
often in the spleen, lungs, bone marrow and kidneys.
Thus, distribution of leukemic cells in mice may
depend on the route of injection, and the different
chemokines secreted by spleen and bone marrow stro-
mal cells [28]. The stromal cells of mice peritoneum
are known from secretion of SDF-1 chemokine
[29,30], and leukemia B-CLL cells express the
CXCR4 receptor. That may, at least partly, explain
homing of leukemia cells at peritoneal site of implan-
tation.
Gradual elimination of leukemic cells from SCID
mice organisms observed in our study was probably
the effect of residual activity of immune system. Even
so, there are no active B or T cells in SCID mice [19],
increased activity of NK cells as well as normal func-
tion of granulocytes and macrophages was reported.
That is why, before implantation of human peripheral
blood cells, mice were treated with cyclophosphamide
in order to suppress residual activity of their own
immune system. Immunosuppressive effect of
cyclophosphamide lasts for about 2 weeks and this
restricted time of our observations to 14 days.
The main problem with B-CLL studies on SCID
mouse model is, that high dose of implanted human
leukemia cells instead of long lasting chronic stage of
B-CLL form, induce rapid death of animals due to sec-
ondary tumours. It was found, that the reason was the
latent form of Epstein-Barr virus (EBV) present in
mice organisms, that activated under immunosuppres-
sive conditions transformation of B-CLL lymphocytes
in aggressive lymphoma cells causing the death of
mice within 8-16 weeks [31]. According Kobayashi et
al. [32] aggressive B-cell lymphomas, causing the
death of animals in short time after B-CLL cells trans-
plantation, origin not from leukemic cells, but from
bystander B cells infected with EBV. In our study, the
evaluation of human DCs effect was studied within
two weeks after B-CLL cells implantation, so previous
to both elimination of inoculated cells, as well as
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Table 5. Effect of human allogeneic dendritic cells (DCallo) or autogeneic dendritic cells (DCauto) implantation on the number of human
cell populations washed out from SCID mouse peritoneal cavity in comparison with that in control SCID mice injected with leukemic
cells only. M = median values, (P25-75) = 25 and 75 percentile values. p = significance of difference between human cell populations in
control animals; p <0.05 assumed as significant.
prospective development of aggressive B-cell lym-
phomas connected with EBV infection.
We observed, that the number of B-CLL cells in
peritoneal fluid was lower in mice treated with allo-
geneic DCs, comparing to the mice that received only
leukemic cells. In this system we observed acute graft
versus host (GVH) response between human allogene-
ic implanted cells within the mouse peritoneal cavity.
This is suggested by the parallel decrease of human B-
CLL and T cells, as allogeneic DCs presentation of
leukemia antigens would activate T cells for prolifera-
tion rather, and not the observed T cells killing.
The observed unresponsiveness of patients own T
lymphocytes to autologous dendritic cells may be part-
ly explained by B-CLL patient's DCs defective phago-
cytosis recently recorded [3]. We observed, that the
vaccination of patients with the irradiated leukemia
cells improve of DCs phagocytotic activity. The autol-
ogous DCs applied in the present SCID mouse experi-
ment were from patients before vaccination. However,
the observed number of T cells at time of analysis was
already nearly 3-times higher in animals treated with
autologous DCs as compared to control animals. The
result suggests crosspresentation of leukemia antigens
by DCs to autologous T cells inducing proliferation of
these cells.
In conclusion, in the present study we established a
model of B-CLL cells implantation into SCID mice,
than on this model the in vivo effects of DCs
immunotherapy were evaluated. In experimental
model, we found tendency to rise of human T cells in
animals treated with autologous DCs that were from
unvaccinated B-CLL patients. These observation con-
firm deficiency of DCs in the unvaccinated patients
recently recorded. 
The result of experiment with allogeneic DCs
resemble acute GVH response. However, the correla-
tion between clinical response and experimental data
from mice model remains equivocal and requires fur-
ther studies. It seems worth to continue the presented
studies on SCID mouse model in order to improve the
efficacy of DCs immunotherapy in B-CLL patients.
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